Sign Out
Although phase II combination trials with conventional chemotherapy agents have been conducted in patients with gynecological malignancies, there is no formal drug interaction studies. Caution should be exercised in the concomitant use of drugs known to interact with conventional doxorubicin HCl. Like other doxorubicin HCl preparations, pegylated liposomal doxorubicin may increase the toxicity of other anti-cancer drugs.
Pegylated liposomal doxorubicin HCl has been administered to 230 cancer patients with solid tumors (including ovarian cancer or breast cancer) as part of combination therapy regimen (combined with either cyclophosphamide, taxanes or vinorelbine). In AIDS-KS patients, it has been reported that conventional doxorubicin HCl exacerbates the cyclophosphamide-induced hemorrhagic cystitis and enhances the hepatotoxicity of 6-mercaptopurine. With caution when use with other anti-cancer drugs, especially those may induce bone marrow suppression.
